T-Cell Engagers — Modern Immune-Based Therapies for Multiple Myeloma | NEJM
Editorial from The New England Journal of Medicine — T-Cell Engagers — Modern Immune-Based Therapies for Multiple Myeloma
Related Articles
MRD as an endpoint for accelerating drug approval in multiple myeloma: updates from the ODAC meeting
On 12th April 2024, a meeting of the US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) was held to assess the use…
April 12, 2024 Meeting of the Oncologic Drugs Advisory Committee (ODAC)
The Committee will discuss the use of minimal residual disease (MRD) as an endpoint in multiple myeloma clinical trials, including considerations regarding t…
Miami Myeloma MRD Meeting 2024
The Miami Myeloma MRD Meeting 2024 brings together leading experts to discuss measurable residual disease (MRD) for multiple myeloma.
Myeloma Patient Expert Q&A: Dr. Ola Landgren – Patient Empowerment Network
Dr. Ola Landgren will discuss emerging myeloma therapies and clinical trials and the latest options for relapsed disease.
Focusing on You: Multiple Myeloma Patient Has “Vision” for Future
Benjamin Diamond, M.D., a hematologist-oncologist who specializes in multiple myeloma at Sylvester Comprehensive Cancer Center, explains what multiple myelom…
Help me Challenge Cancer!
The DCC is a year-round collective community movement to raise money in support of Sylvester Comprehensive Cancer Center at the University of Miami. With your…
Miami Myeloma Roundtable – HealthTree for Multiple Myeloma
Join us in-person or online for a Myeloma Roundtable with Top Myeloma Experts in Miami on Sat, April 20th, 2024.
Welcome to S. Florida Multiple Myeloma Conference
Book your hotel room for the event at special rates, available here on an exclusive basis.
Miami 2024 – PleXus Communications
PleXus has been a premier source of continuing medical education for hematology/oncology professionals through various mediums (i.e., symposia, live hospital-based activities, manuscripts, online activities, etc.)…